| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
Departments of Pathology and Laboratory Medicine [G. C., D. S., A. P., L. I., P. S. M.], Human Genetics and Biostatistics [S. H.] Henry E. Singleton Brain Cancer Research Program [T. F. C., P. S. M.], and The Howard Hughes Medical Institute [C. L. S.], David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90095; Department of Clinical Chemistry, University of Helsinki, Helsinki, Finland FIN-00014 [A. P.]; and Cell Signaling Technologies, Beverly, Massachusetts 01915 [K. C., B. S.]
Deregulated signaling through the phosphatidylinositol 3'-kinase (PI3K) pathway is common in many types of cancer, including glioblastoma. Dissecting the molecular events associated with activation of this pathway in glioblastoma patients in vivo presents an important challenge that has implications for the development and clinical testing of PI3K pathway inhibitors. Using an immunohistochemical analysis applied to a tissue microarray, we performed hierarchical clustering and multidimensional scaling, as well as univariate and multivariate analyses, to dissect the PI3K pathway in vivo. We demonstrate that loss of the tumor suppressor protein PTEN, which antagonizes PI3K pathway activation, is highly correlated with activation of the main PI3K effector Akt in vivo. We also show that Akt activation is significantly correlated with phosphorylation of mammalian target of rapamycin (mTOR), the family of forkhead transcription factors (FOXO1, FOXO3a, and FOXO4), and S6, which are thought to promote its effects. Expression of the mutant epidermal growth factor receptor vIII is also tightly correlated with phosphorylation of these effectors, demonstrating an additional route to PI3K pathway activation in glioblastomas in vivo. These results provide the first dissection of the PI3K pathway in glioblastoma in vivo and suggest an approach to stratifying patients for targeted kinase inhibitor therapy.
This article has been cited by other articles:
![]() |
P. H. Huang, A. M. Xu, and F. M. White Oncogenic EGFR Signaling Networks in Glioma Sci. Signal., September 8, 2009; 2(87): re6 - re6. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. V. Lu, S. Zhu, A. Cvrljevic, T. T. Huang, S. Sarkaria, D. Ahkavan, J. Dang, E. B. Dinca, S. B. Plaisier, I. Oderberg, et al. Fyn and Src Are Effectors of Oncogenic Epidermal Growth Factor Receptor Signaling in Glioblastoma Patients Cancer Res., September 1, 2009; 69(17): 6889 - 6898. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Guo, I. J. Hildebrandt, R. M. Prins, H. Soto, M. M. Mazzotta, J. Dang, J. Czernin, J. Y.-J. Shyy, A. D. Watson, M. Phelps, et al. The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis PNAS, August 4, 2009; 106(31): 12932 - 12937. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. W. Ronellenfitsch, D. P. Brucker, M. C. Burger, S. Wolking, F. Tritschler, J. Rieger, W. Wick, M. Weller, and J. P. Steinbach Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death Brain, June 1, 2009; 132(6): 1509 - 1522. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-S. Guillamo, S. de Bouard, S. Valable, L. Marteau, P. Leuraud, Y. Marie, M.-F. Poupon, J.-J. Parienti, E. Raymond, and M. Peschanski Molecular Mechanisms Underlying Effects of Epidermal Growth Factor Receptor Inhibition on Invasion, Proliferation, and Angiogenesis in Experimental Glioma Clin. Cancer Res., June 1, 2009; 15(11): 3697 - 3704. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. A. Tyler, N. Gangoli, P. Gokina, H. A. Kim, M. Covey, S. W. Levison, and T. L. Wood Activation of the Mammalian Target of Rapamycin (mTOR) Is Essential for Oligodendrocyte Differentiation J. Neurosci., May 13, 2009; 29(19): 6367 - 6378. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. van den Bent, A. A. Brandes, R. Rampling, M. C.M. Kouwenhoven, J. M. Kros, A. F. Carpentier, P. M. Clement, M. Frenay, M. Campone, J.-F. Baurain, et al. Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034 J. Clin. Oncol., March 10, 2009; 27(8): 1268 - 1274. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Klatte, D. B. Seligson, J. LaRochelle, B. Shuch, J. W. Said, S. B. Riggs, N. Zomorodian, F. F. Kabbinavar, A. J. Pantuck, and A. S. Belldegrun Molecular Signatures of Localized Clear Cell Renal Cell Carcinoma to Predict Disease-Free Survival after Nephrectomy Cancer Epidemiol. Biomarkers Prev., March 1, 2009; 18(3): 894 - 900. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Li, A. Dutra, E. Pak, J. E. Labrie III, R. M. Gerstein, P. P. Pandolfi, L. D. Recht, and A. H. Ross EGFRvIII expression and PTEN loss synergistically induce chromosomal instability and glial tumors Neuro-oncol, January 1, 2009; 11(1): 9 - 21. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Marsh, P. Mukherjee, and T. N. Seyfried Akt-Dependent Proapoptotic Effects of Dietary Restriction on Late-Stage Management of a Phosphatase and Tensin Homologue/Tuberous Sclerosis Complex 2-Deficient Mouse Astrocytoma Clin. Cancer Res., December 1, 2008; 14(23): 7751 - 7762. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Williams Paul Mischel: All about brains J. Cell Biol., October 22, 2008; 181(7): 1044 - 1045. [Full Text] [PDF] |
||||
![]() |
T. Martens, Y. Laabs, H. S. Gunther, D. Kemming, Z. Zhu, L. Witte, C. Hagel, M. Westphal, and K. Lamszus Inhibition of Glioblastoma Growth in a Highly Invasive Nude Mouse Model Can Be Achieved by Targeting Epidermal Growth Factor Receptor but not Vascular Endothelial Growth Factor Receptor-2 Clin. Cancer Res., September 1, 2008; 14(17): 5447 - 5458. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Yang, M. J. Clarke, B. L. Carlson, A. C. Mladek, M. A. Schroeder, P. Decker, W. Wu, G. J. Kitange, P. T. Grogan, J. M. Goble, et al. PTEN Loss Does Not Predict for Response to RAD001 (Everolimus) in a Glioblastoma Orthotopic Xenograft Test Panel Clin. Cancer Res., June 15, 2008; 14(12): 3993 - 4001. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. K. Thorarinsdottir, M. Santi, R. McCarter, E. J. Rushing, R. Cornelison, A. Jales, and T. J. MacDonald Protein Expression of Platelet-Derived Growth Factor Receptor Correlates with Malignant Histology and PTEN with Survival in Childhood Gliomas Clin. Cancer Res., June 1, 2008; 14(11): 3386 - 3394. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. C. Brantley and E. N. Benveniste Signal Transducer and Activator of Transcription-3: A Molecular Hub for Signaling Pathways in Gliomas Mol. Cancer Res., May 1, 2008; 6(5): 675 - 684. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. A Dennis Targeting Akt in Cancer: Promise, Progress, and Potential Pitfalls Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 25 - 35. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. T. Jindra, A. Hsueh, L. Hong, D. Gjertson, X.-D. Shen, F. Gao, J. Dang, P. S. Mischel, W. M. Baldwin III, M. C. Fishbein, et al. Anti-MHC Class I Antibody Activation of Proliferation and Survival Signaling in Murine Cardiac Allografts J. Immunol., February 15, 2008; 180(4): 2214 - 2224. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. de la Iglesia, G. Konopka, S. V. Puram, J. A. Chan, R. M. Bachoo, M. J. You, D. E. Levy, R. A. DePinho, and A. Bonni Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway Genes & Dev., February 15, 2008; 22(4): 449 - 462. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Yaba, V. Bianchi, A. Borini, and J. Johnson A Putative Mitotic Checkpoint Dependent on mTOR Function Controls Cell Proliferation and Survival in Ovarian Granulosa Cells Reproductive Sciences, February 1, 2008; 15(2): 128 - 138. [Abstract] [PDF] |
||||
![]() |
K. Yoshimoto, J. Dang, S. Zhu, D. Nathanson, T. Huang, R. Dumont, D. B. Seligson, W. H. Yong, Z. Xiong, N. Rao, et al. Development of a Real-time RT-PCR Assay for Detecting EGFRvIII in Glioblastoma Samples Clin. Cancer Res., January 15, 2008; 14(2): 488 - 493. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Sathornsumetee, Y. Cao, J. E. Marcello, J. E. Herndon II, R. E. McLendon, A. Desjardins, H. S. Friedman, M. W. Dewhirst, J. J. Vredenburgh, and J. N. Rich Tumor Angiogenic and Hypoxic Profiles Predict Radiographic Response and Survival in Malignant Astrocytoma Patients Treated With Bevacizumab and Irinotecan J. Clin. Oncol., January 10, 2008; 26(2): 271 - 278. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. S. Sarkaria, M. F. Zakowski, D. Pham, M. Hezel, M. I. Ebright, S. Chuai, E. S. Venkatraman, M. G. Kris, V. W. Rusch, and B. Singh Epidermal Growth Factor Receptor Signaling in Adenocarcinomas With Bronchioloalveolar Components Ann. Thorac. Surg., January 1, 2008; 85(1): 216 - 223. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Zhang, J. Yu, H. Pan, P. Hu, Y. Hao, W. Cai, H. Zhu, A. D. Yu, X. Xie, D. Ma, et al. Small molecule regulators of autophagy identified by an image-based high-throughput screen PNAS, November 27, 2007; 104(48): 19023 - 19028. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. B. Furnari, T. Fenton, R. M. Bachoo, A. Mukasa, J. M. Stommel, A. Stegh, W. C. Hahn, K. L. Ligon, D. N. Louis, C. Brennan, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment Genes & Dev., November 1, 2007; 21(21): 2683 - 2710. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ishiuchi, Y. Yoshida, K. Sugawara, M. Aihara, T. Ohtani, T. Watanabe, N. Saito, K. Tsuzuki, H. Okado, A. Miwa, et al. Ca2+-Permeable AMPA Receptors Regulate Growth of Human Glioblastoma via Akt Activation J. Neurosci., July 25, 2007; 27(30): 7987 - 8001. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. D. Kao, Z. Jiang, A. M. Fernandes, A. K. Gupta, and A. Maity Inhibition of Phosphatidylinositol-3-OH Kinase/Akt Signaling Impairs DNA Repair in Glioblastoma Cells following Ionizing Radiation J. Biol. Chem., July 20, 2007; 282(29): 21206 - 21212. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. E. Pelloski, K. V. Ballman, A. F. Furth, L. Zhang, E. Lin, E. P. Sulman, K. Bhat, J. M. McDonald, W.K. A. Yung, H. Colman, et al. Epidermal Growth Factor Receptor Variant III Status Defines Clinically Distinct Subtypes of Glioblastoma J. Clin. Oncol., June 1, 2007; 25(16): 2288 - 2294. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Jiang, N. Pore, G. J. Cerniglia, R. Mick, M.-M. Georgescu, E. J. Bernhard, S. M. Hahn, A. K. Gupta, and A. Maity Phosphatase and Tensin Homologue Deficiency in Glioblastoma Confers Resistance to Radiation and Temozolomide that Is Reversed by the Protease Inhibitor Nelfinavir Cancer Res., May 1, 2007; 67(9): 4467 - 4473. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Zhou, R. Miki, M. Eeva, F. M. Fike, D. Seligson, L. Yang, A. Yoshimura, M. A. Teitell, C. A.M. Jamieson, and N. A. Cacalano Reciprocal Regulation of SOCS 1 and SOCS3 Enhances Resistance to Ionizing Radiation in Glioblastoma Multiforme Clin. Cancer Res., April 15, 2007; 13(8): 2344 - 2353. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Faury, A. Nantel, S. E. Dunn, M.-C. Guiot, T. Haque, P. Hauser, M. Garami, L. Bognar, Z. Hanzely, P. P. Liberski, et al. Molecular Profiling Identifies Prognostic Subgroups of Pediatric Glioblastoma and Shows Increased YB-1 Expression in Tumors J. Clin. Oncol., April 1, 2007; 25(10): 1196 - 1208. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Failly, S. Korur, V. Egler, J.-L. Boulay, M. M. Lino, R. Imber, and A. Merlo Combination of sublethal concentrations of epidermal growth factor receptor inhibitor and microtubule stabilizer induces apoptosis of glioblastoma cells Mol. Cancer Ther., February 1, 2007; 6(2): 773 - 781. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Opel, C. Poremba, T. Simon, K.-M. Debatin, and S. Fulda Activation of Akt Predicts Poor Outcome in Neuroblastoma Cancer Res., January 15, 2007; 67(2): 735 - 745. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. K. Mellinghoff, T. F. Cloughesy, and P. S. Mischel PTEN-Mediated Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Clin. Cancer Res., January 15, 2007; 13(2): 378 - 381. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Lam, A. J. Pantuck, A. S. Belldegrun, and R. A. Figlin Protein Expression Profiles in Renal Cell Carcinoma: Staging, Prognosis, and Patient Selection for Clinical Trials Clin. Cancer Res., January 15, 2007; 13(2): 703s - 708s. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Horvath, B. Zhang, M. Carlson, K. V. Lu, S. Zhu, R. M. Felciano, M. F. Laurance, W. Zhao, S. Qi, Z. Chen, et al. Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target PNAS, November 14, 2006; 103(46): 17402 - 17407. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. C. Birle and D. W. Hedley Signaling interactions of rapamycin combined with erlotinib in cervical carcinoma xenografts. Mol. Cancer Ther., October 1, 2006; 5(10): 2494 - 2502. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Y. Wang, K. V. Lu, S. Zhu, E. Q. Dia, I. Vivanco, G. M. Shackleford, W. K. Cavenee, I. K. Mellinghoff, T. F. Cloughesy, C. L. Sawyers, et al. Mammalian Target of Rapamycin Inhibition Promotes Response to Epidermal Growth Factor Receptor Kinase Inhibitors in PTEN-Deficient and PTEN-Intact Glioblastoma Cells Cancer Res., August 15, 2006; 66(16): 7864 - 7869. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. F. Cloughesy, P. Y. Wen, H. I. Robins, S. M. Chang, M. D. Groves, K. L. Fink, L. Junck, D. Schiff, L. Abrey, M. R. Gilbert, et al. Phase II Trial of Tipifarnib in Patients With Recurrent Malignant Glioma Either Receiving or Not Receiving Enzyme-Inducing Antiepileptic Drugs: A North American Brain Tumor Consortium Study J. Clin. Oncol., August 1, 2006; 24(22): 3651 - 3656. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. E. Pelloski, E Lin, L. Zhang, W.K. A. Yung, H. Colman, J.-L. Liu, S. Y. Woo, A. B. Heimberger, D. Suki, M. Prados, et al. Prognostic Associations of Activated Mitogen-Activated Protein Kinase and Akt Pathways in Glioblastoma. Clin. Cancer Res., July 1, 2006; 12(13): 3935 - 3941. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Riemenschneider, R. A. Betensky, S. M. Pasedag, and D. N. Louis AKT Activation in Human Glioblastomas Enhances Proliferation via TSC2 and S6 Kinase Signaling Cancer Res., June 1, 2006; 66(11): 5618 - 5623. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. de la Pena, W. E. Burgan, D. J. Carter, M. G. Hollingshead, M. Satyamitra, K. Camphausen, and P. J. Tofilon Inhibition of Akt by the alkylphospholipid perifosine does not enhance the radiosensitivity of human glioma cells. Mol. Cancer Ther., June 1, 2006; 5(6): 1504 - 1510. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Powis, N. Ihle, and D. L. Kirkpatrick Practicalities of drugging the phosphatidylinositol-3-kinase/akt cell survival signaling pathway. Clin. Cancer Res., May 15, 2006; 12(10): 2964 - 2966. [Full Text] [PDF] |
||||
![]() |
D. A. Reardon, J. N. Rich, H. S. Friedman, and D. D. Bigner Recent Advances in the Treatment of Malignant Astrocytoma J. Clin. Oncol., March 10, 2006; 24(8): 1253 - 1265. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Reardon, J. A. Quinn, J. J. Vredenburgh, S. Gururangan, A. H. Friedman, A. Desjardins, S. Sathornsumetee, J. E. Herndon II, J. M. Dowell, R. E. McLendon, et al. Phase 1 Trial of Gefitinib Plus Sirolimus in Adults with Recurrent Malignant Glioma Clin. Cancer Res., February 1, 2006; 12(3): 860 - 868. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. B. Ramnarain, S. Park, D. Y. Lee, K. J. Hatanpaa, S. O. Scoggin, H. Otu, T. A. Libermann, J. M. Raisanen, R. Ashfaq, E. T. Wong, et al. Differential Gene Expression Analysis Reveals Generation of an Autocrine Loop by a Mutant Epidermal Growth Factor Receptor in Glioma Cells Cancer Res., January 15, 2006; 66(2): 867 - 874. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-L. Tso, W. A. Freije, A. Day, Z. Chen, B. Merriman, A. Perlina, Y. Lee, E. Q. Dia, K. Yoshimoto, P. S. Mischel, et al. Distinct Transcription Profiles of Primary and Secondary Glioblastoma Subgroups Cancer Res., January 1, 2006; 66(1): 159 - 167. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Lee, C. B. Fuhrman, V. Planelles, M. R. Peltier, D. K. Gaffney, A. P. Soisson, M. K. Dodson, H. D. Tolley, C. L. Green, and K. A. Zempolich Phosphatidylinositol 3-Kinase Inhibition by LY294002 Radiosensitizes Human Cervical Cancer Cell Lines Clin. Cancer Res., January 1, 2006; 12(1): 250 - 256. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Oda, D. Stokoe, Y. Taketani, and F. McCormick High Frequency of Coexistent Mutations of PIK3CA and PTEN Genes in Endometrial Carcinoma Cancer Res., December 1, 2005; 65(23): 10669 - 10673. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. N. Rich, S. Sathornsumetee, S. T. Keir, M. W. Kieran, A. Laforme, A. Kaipainen, R. E. McLendon, M. W. Graner, B.K. A. Rasheed, L. Wang, et al. ZD6474, a Novel Tyrosine Kinase Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor, Inhibits Tumor Growth of Multiple Nervous System Tumors Clin. Cancer Res., November 15, 2005; 11(22): 8145 - 8157. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. K. Mellinghoff, M. Y. Wang, I. Vivanco, D. A. Haas-Kogan, S. Zhu, E. Q. Dia, K. V. Lu, K. Yoshimoto, J. H.Y. Huang, D. J. Chute, et al. Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors. N. Engl. J. Med., November 10, 2005; 353(19): 2012 - 2024. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. V. Lu, K. A. Jong, G. Y. Kim, J. Singh, E. Q. Dia, K. Yoshimoto, M. Y. Wang, T. F. Cloughesy, S. F. Nelson, and P. S. Mischel Differential Induction of Glioblastoma Migration and Growth by Two Forms of Pleiotrophin J. Biol. Chem., July 22, 2005; 280(29): 26953 - 26964. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. G. Chiang and R. T. Abraham Phosphorylation of Mammalian Target of Rapamycin (mTOR) at Ser-2448 Is Mediated by p70S6 Kinase J. Biol. Chem., July 8, 2005; 280(27): 25485 - 25490. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. A. Rege, C. Y. Fears, and C. L. Gladson Endogenous inhibitors of angiogenesis in malignant gliomas: Nature's antiangiogenic therapy Neuro-oncol, April 1, 2005; 7(2): 106 - 121. [Abstract] [PDF] |
||||
![]() |
F. Lefranc, J. Brotchi, and R. Kiss Possible Future Issues in the Treatment of Glioblastomas: Special Emphasis on Cell Migration and the Resistance of Migrating Glioblastoma Cells to Apoptosis J. Clin. Oncol., April 1, 2005; 23(10): 2411 - 2422. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Wu, D. C. Birle, and I. F. Tannock Effects of the Mammalian Target of Rapamycin Inhibitor CCI-779 Used Alone or with Chemotherapy on Human Prostate Cancer Cells and Xenografts Cancer Res., April 1, 2005; 65(7): 2825 - 2831. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Vignot, S. Faivre, D. Aguirre, and E. Raymond mTOR-targeted therapy of cancer with rapamycin derivatives Ann. Onc., April 1, 2005; 16(4): 525 - 537. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.L. SAWYERS Making Progress through Molecular Attacks on Cancer Cold Spring Harb Symp Quant Biol, January 1, 2005; 70(0): 479 - 482. [Abstract] [PDF] |
||||
![]() |
R. K. Goudar, Q. Shi, M. D. Hjelmeland, S. T. Keir, R. E. McLendon, C. J. Wikstrand, E. D. Reese, C. A. Conrad, P. Traxler, H. A. Lane, et al. Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition Mol. Cancer Ther., January 1, 2005; 4(1): 101 - 112. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. V. Thomas, S. Horvath, B. L. Smith, K. Crosby, L. A. Lebel, M. Schrage, J. Said, J. De Kernion, R. E. Reiter, and C. L. Sawyers Antibody-Based Profiling of the Phosphoinositide 3-Kinase Pathway in Clinical Prostate Cancer Clin. Cancer Res., December 15, 2004; 10(24): 8351 - 8356. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Shi, S. Bao, J. A. Maxwell, E. D. Reese, H. S. Friedman, D. D. Bigner, X.-F. Wang, and J. N. Rich Secreted Protein Acidic, Rich in Cysteine (SPARC), Mediates Cellular Survival of Gliomas through AKT Activation J. Biol. Chem., December 10, 2004; 279(50): 52200 - 52209. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. K. Broderick, C. Di, T. J. Parrett, Y. R. Samuels, J. M. Cummins, R. E. McLendon, D. W. Fults, V. E. Velculescu, D. D. Bigner, and H. Yan Mutations of PIK3CA in Anaplastic Oligodendrogliomas, High-Grade Astrocytomas, and Medulloblastomas Cancer Res., August 1, 2004; 64(15): 5048 - 5050. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Chakravarti, G. Zhai, Y. Suzuki, S. Sarkesh, P. M. Black, A. Muzikansky, and J. S. Loeffler The Prognostic Significance of Phosphatidylinositol 3-Kinase Pathway Activation in Human Gliomas J. Clin. Oncol., May 15, 2004; 22(10): 1926 - 1933. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. B. Knobbe, J. Reifenberger, B. Blaschke, and G. Reifenberger Hypermethylation and Transcriptional Downregulation of the Carboxyl-Terminal Modulator Protein Gene in Glioblastomas J Natl Cancer Inst, March 17, 2004; 96(6): 483 - 486. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. L. Sawyers Opportunities and challenges in the development of kinase inhibitor therapy for cancer Genes & Dev., December 15, 2003; 17(24): 2998 - 3010. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |